BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34476768)

  • 1. Leveraging Case Narratives to Enhance Patient Age Ascertainment from Adverse Event Reports.
    Pham P; Cheng C; Wu E; Kim I; Zhang R; Ma Y; Kortepeter CM; Muñoz MA
    Pharmaceut Med; 2021 Sep; 35(5):307-316. PubMed ID: 34476768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System.
    Marwitz K; Jones SC; Kortepeter CM; Dal Pan GJ; Muñoz MA
    Drug Saf; 2020 May; 43(5):457-465. PubMed ID: 31981082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility.
    Muñoz MA; Dal Pan GJ; Wei YJ; Delcher C; Xiao H; Kortepeter CM; Winterstein AG
    Drug Saf; 2020 Apr; 43(4):329-338. PubMed ID: 31912439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology.
    Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R
    J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation and comparison of two text mining methods with a standard pharmacovigilance method for signal detection of medication errors.
    Eskildsen NK; Eriksson R; Christensen SB; Aghassipour TS; Bygsø MJ; Brunak S; Hansen SL
    BMC Med Inform Decis Mak; 2020 May; 20(1):94. PubMed ID: 32448248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automatic Extraction of Comprehensive Drug Safety Information from Adverse Drug Event Narratives in the Korea Adverse Event Reporting System Using Natural Language Processing Techniques.
    Kim S; Kang T; Chung TK; Choi Y; Hong Y; Jung K; Lee H
    Drug Saf; 2023 Aug; 46(8):781-795. PubMed ID: 37330415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Pediatric Reports in the US Food and Drug Administration Adverse Event Reporting System from 2010-2020: A Cross-Sectional Study.
    Phan M; Cheng C; Dang V; Wu E; Muñoz MA
    Ther Innov Regul Sci; 2023 Sep; 57(5):1062-1073. PubMed ID: 37351842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks.
    van Stekelenborg J; Kara V; Haack R; Vogel U; Garg A; Krupp M; Gofman K; Dreyfus B; Hauben M; Bate A
    Drug Saf; 2023 Jan; 46(1):39-52. PubMed ID: 36565374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a multivariate prediction model to identify individual case safety reports which require clinical review.
    Gosselt HR; Bazelmans EA; Lieber T; van Hunsel FPAM; Härmark L
    Pharmacoepidemiol Drug Saf; 2022 Dec; 31(12):1300-1307. PubMed ID: 36251280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
    de Bie S; Ferrajolo C; Straus SM; Verhamme KM; Bonhoeffer J; Wong IC; Sturkenboom MC;
    PLoS One; 2015; 10(6):e0130399. PubMed ID: 26090678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric Drug Safety Surveillance: A 10-Year Analysis of Adverse Drug Reaction Reporting Data in Calabria, Southern Italy.
    Leporini C; De Sarro C; Palleria C; Caccavo I; Piro B; Citraro R; De Sarro G
    Drug Saf; 2022 Nov; 45(11):1381-1402. PubMed ID: 36112324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorting Through the Safety Data Haystack: Using Machine Learning to Identify Individual Case Safety Reports in Social-Digital Media.
    Comfort S; Perera S; Hudson Z; Dorrell D; Meireis S; Nagarajan M; Ramakrishnan C; Fine J
    Drug Saf; 2018 Jun; 41(6):579-590. PubMed ID: 29446035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.
    Stergiopoulos S; Fehrle M; Caubel P; Tan L; Jebson L
    Pharmaceut Med; 2019 Dec; 33(6):499-510. PubMed ID: 31933240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leveraging Machine Learning to Facilitate Individual Case Causality Assessment of Adverse Drug Reactions.
    Cherkas Y; Ide J; van Stekelenborg J
    Drug Saf; 2022 May; 45(5):571-582. PubMed ID: 35579819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®.
    Ampadu HH; Hoekman J; de Bruin ML; Pal SN; Olsson S; Sartori D; Leufkens HG; Dodoo AN
    Drug Saf; 2016 Apr; 39(4):335-45. PubMed ID: 26754924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates of spontaneous reports of adverse drug reactions for drugs reported in children: a cross-sectional study with data from the Swedish adverse drug reaction database and the Swedish Prescribed Drug Register.
    Wallerstedt SM; Brunlöf G; Sundström A
    Drug Saf; 2011 Aug; 34(8):669-82. PubMed ID: 21751827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years.
    Karrer JE; Giovannoni L; Kullak-Ublick GA; Weiler S
    Swiss Med Wkly; 2019 Jun; 149():w20085. PubMed ID: 31256417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Key elements in adverse drug interaction safety signals: an assessment of individual case safety reports.
    Strandell J; Norén GN; Hägg S
    Drug Saf; 2013 Jan; 36(1):63-70. PubMed ID: 23315297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
    Zhou Z; Hultgren KE
    JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.